May 20,2021

2021 ASCO Annual Meeting Publishes Two Abstracts Based on Real-World Patient Data Generated from Belong.Life's Connected Health Platform

Belong.Life, developer of social and professional networks for managing and navigating diseases, and the creator of the world's largest social network for cancer patients, today announced that the American Society of Clinical Oncology (ASCO) has published two abstracts in its 2021 Annual Meeting Abstract Book based on data aggregated from the Belong Beating Cancer Together app. The abstracts provide key insights into significant challenges for oncology patients, including sexuality and clinical trial participation.

CLINICAL STUDY

#mobile app

#rwd

View Analyst & Ambassador Comments
Go to original news
May 06,2021

CoolClinical.com has Developed the First AI System for Predicting Outcomes of Cancer Treatment

Cool Clinical announced the release of the publication on the first Artificial Intelligence system for predicting outcomes of cancer treatment, using data from clinical trials. This is a breakthrough for AI approaches to cancer treatment, because clinical trial data are widely available; this research therefore shows the way for precision medicine systems for cancer which are very feasible to develop.

PRODUCT

#ai/software

View Analyst & Ambassador Comments
Go to original news
May 24,2021

Grand Challenge Research Harnesses AI to Fight Breast Cancer

Breast cancer has recently overtaken lung cancer to become the most common cancer globally, according to the World Health Organization. Advancing the fight against breast cancer, the BreastPathQ Challenge was launched at SPIE Medical Imaging 2019 to support the development of computer-aided diagnosis for assessing breast cancer pathology.

CLINICAL STUDY

#ai/software

View Analyst & Ambassador Comments
Go to original news
May 08,2021

Impact of assessment frequency of patient-reported outcomes: an observational study using an eHealth platform in cancer patients

The evaluation of patient-reported outcomes (PRO) in cancer has proven relevant positive clinical impact on patients’ communication with healthcare professionals, decision-making for management, well-being, and overall survival. However, the optimal frequency of PRO assessment has yet to be defined. Based on the assumption that more frequent sampling would enhance accuracy, the study aimed at identifying the optimal sampling frequency that does not miss clinically relevant insight.

CLINICAL STUDY

#platform

View Analyst & Ambassador Comments
Go to original news
May 28,2021

Increasing physical activity in Cancer Survivors through a Text-messaging Exercise motivation Program (ICanSTEP)

Cancer survivors are often sedentary. Self-monitoring may promote physical activity through self-activation. The researchers conducted a pilot trial to evaluate whether wearable activity tracker with personalized text message feedback would increase physical activity. Each participant received an activity tracker and daily text messages personalized to their activity level. The results showed that the intervention was well-accepted with a high completion rate at 3 months and continued self-use at 6 months.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
May 01,2021

Flatiron Health Announces Research to be Presented at American Society of Clinical Oncology 2021 Annual Meeting

Flatiron Health today announced eight abstracts have been accepted for presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 4-8.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
May 12,2021

Voluntis receives CE Mark for new version of Oleena with expanded clinical intelligence

Voluntis today announced that it has received the CE mark for a new version of Oleena featuring expanded clinical intelligence. Oleena is Voluntis’ proprietary digital therapeutic that supports patients in the self-management of their symptoms in combination with a wide range of cancer treatments, while allowing healthcare teams to remotely monitor the progress of the disease.

REGULATORY CE MARK

#dtx

View Analyst & Ambassador Comments
Go to original news
May 12,2021

Data From Incyte’s Oncology Portfolio Accepted for Presentation at the 2021 EHA Virtual Congress

Incyte (Nasdaq:INCY) today announced that multiple abstracts highlighting data from its oncology portfolio will be presented during the upcoming European Hematology Association (EHA) 2021 Virtual Congress, held virtually from June 9-17, 2021.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
May 18,2021

Astellas to Present Data from Expanding Oncology Portfolio During the 2021 ASCO Annual Meeting

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) will share new data across its oncology portfolio during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting from June 4-8, 2021.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
May 19,2021

Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 2021 ASCO Annual Meeting

Incyte (Nasdaq: INCY) today announced that multiple abstracts highlighting data from its oncology portfolio will be presented during the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, held virtually from June 4-8, 2021.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY